Amgen’s (AMGN) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against heart attack and stroke in high risk patients.
Prior to the FOURIER trial, which confirmed the effect of Repatha in lowering cardiovascular events, including heart attack and stroke, other clinical trial data led to the FDA approval of Repatha limited to the following indications: 1) adjunct to diet and maximally tolerated statin therapy for heterozygous familial hypercholesterolemia (HeFH), and 2) patients with clinical atherosclerotic cardiovascular disease (CVD) in patients who require additional lowering . . .
This content is for paid subscribers.
Today’s Highlights March 21, 2017